RICERCA
AUTORI
RIVISTE
Sfoglia per RIVISTA
THE LANCET. ONCOLOGY
Collezione AOU San Luigi di Orbassano
Items : 12
2024
AOU San Luigi di Orbassano
Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; et alii...
Fluorescence in prostate cancer surgery. in The Lancet. Oncology / Lancet Oncol. 2023 May;24(5):417-419. doi: 10.1016/S1470-2045(23)00164-X.
2023
AOU San Luigi di Orbassano
Amparore D; Porpiglia F;
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.
2021
AOU San Luigi di Orbassano
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K;
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
2019
AOU San Luigi di Orbassano
Au KH; Moro-Sibilot D; Shih JY; Yoh K; Imamura F; Nadal E; Novello S; Park K; Chiu CH; Paz-Ares L; Ponce Aix S; Nishio M; Seto T; Garon EB; Nakagawa K; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.
2018
AOU San Luigi di Orbassano
ASL Alessandria
Bearz A; Muzio A; Novello S; Taylor P; Shah R; Tiseo M; Bidoli P; Polychronis A; Jassem J; Grossi F; Favaretto A; Gaafar RM; Gregorc V; Lambiase A; O'Brien M; Greillier L; Fontana F; Salini G;
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.
2017
AOU San Luigi di Orbassano
Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E;
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. in The Lancet. Oncology / Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
2016
AOU San Luigi di Orbassano
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Ponatinib for chronic myeloid leukaemia: future perspectives. in The Lancet. Oncology / Lancet Oncol. 2016 May;17(5):546-7. doi: 10.1016/S1470-2045(16)30064-X. Epub 2016 Apr 12.
2016
AOU San Luigi di Orbassano
Fava C; Saglio G;
LUX-Lung: determining the best EGFR inhibitor in NSCLC? in The Lancet. Oncology / Lancet Oncol. 2015 Feb;16(2):118-9. doi: 10.1016/S1470-2045(14)71196-9. Epub 2015 Jan 12.
2015
AOU San Luigi di Orbassano
Rossi A; Di Maio M;
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.
2014
AOU San Luigi di Orbassano
ASL Città di Torino
Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H;
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. in The Lancet. Oncology / Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9.
2014
AOU San Luigi di Orbassano
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation. in The Lancet. Oncology / Lancet Oncol. 2006 Feb;7(2):186-7. doi: 10.1016/S1470-2045(06)70582-4.
2006
AOU San Luigi di Orbassano
Saini A; Berruti A; Sperone P; Bitossi R; Tampellini M; Dogliotti L; Gorzegno G;